eMedicine Specialties > Dermatology > Lymphoma and Related Processes

Cutaneous T-Cell Lymphoma

Author: Robert A Schwartz, MD, MPH, Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Coauthor(s): W Clark Lambert, MD, PhD, Professor and Head, Dermatopathology, Departments of Pathology and Dermatology, UMDNJ-New Jersey Medical School
Contributor Information and Disclosures

Updated: Nov 10, 2009

Introduction

Background

Cutaneous T-cell lymphomas (CTCLs) are the largest group of cutaneous lymphomas, representing 65% of all cutaneous lymphomas. The World Health Organization (WHO)/European Organization for Research and Treatment of Cancer (EORTC) classification (WHO-EORTC classification) is used to categorize CTCLs.1,2,3 However, a substantial subset of T-cell primary cutaneous lymphomas remains that cannot be classified beyond the unspecified peripheral T-cell category, some of which may have an aggressive course.4

Mature T-cell and natural killer (NK) cell neoplasms according to the WHO-EORTC classification are as follows:

  • Mycosis fungoides
    • Variants of mycosis fungoides (MF)
      • Pagetoid reticulosis (localized disease)
      • Follicular, syringotropic, granulomatous variant
    • Subtype of MF - Granulomatous slack skin (GSS) syndrome
  • Sézary syndrome
  • CD30+ T-cell lymphoproliferative disorders of the skin
    • Lymphomatoid papulosis
    • Primary cutaneous anaplastic large cell lymphoma
  • Subcutaneous panniculitislike T-cell lymphoma
  • Primary cutaneous peripheral T-cell lymphoma (PTL), unspecified
    • Subtypes of PTL
      • Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma (provisional)
      • Cutaneous gamma/delta-positive T-cell lymphoma (CGD-TCL) (provisional)
      • Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (provisional)
  • Extranodal NK/T-cell lymphoma, nasal type
    • Variant - Hydroa vacciniformialike lymphoma
  • Adult T-cell leukemia/lymphoma
  • Angioimmunoblastic T-cell lymphoma

CTCL, most commonly seen as MF, is a relatively common clonal expansion of T helper cells and, more rarely, T suppressor/killer cells or NK cells, that usually appears as a widespread, chronic, cutaneous eruption. MF itself is often an epidermotropic disorder characterized by evolution of patches into plaques and tumors composed of small- to medium-sized skin-homing T cells, some (or, rarely, all) of which have convoluted, cerebriform nuclei.

Pagetoid reticulosis is a variant of MF and is characterized by the presence of localized patches or plaques with an intraepidermal proliferation of neoplastic T cells. The term pagetoid reticulosis should be restricted to the localized type (Woringer-Kolopp type) and should not be used to describe the disseminated type (Ketron-Goodman type). Generalized cases should probably be classified as aggressive epidermotropic CD8+ CTCL, CGD-TCL, or tumor-stage MF.5

GSS syndrome is a rare subtype of CTCL characterized by the slow development of folds of lax skin in the major skin folds and, histologically, by an infiltrate of clonal T cells, with exceptionally large multinucleated giant cells sometimes showing inclusion of fragmented elastic fibers. Granulomatous CTCLs are rare, so limited data on the clinicopathological and prognostic features are available.6 Patients with granulomatous MF and GSS display overlapping histologic features and differ clinically by the development of bulky skin folds in GSS.

Sézary syndrome (SS) has been defined historically by the triad of erythroderma, generalized lymphadenopathy, and the presence of neoplastic T cells (Sézary cells) in skin, lymph nodes, and peripheral blood. Some authorities believe the diagnosis of SS should include one or more of the following7 :

  • An absolute Sézary cell count of least 1000/µL
  • Demonstration of immunophenotypical abnormalities (an expanded CD4+ T-cell population resulting in a CD4/CD8 ratio of more than 10:1; loss of any or all of the T-cell antigens CD2, CD3, CD4, CD5; or loss of both CD4 and CD5)
  • Demonstration of a T-cell clone in the peripheral blood by molecular or cytogenetic methods

SS is an erythrodermic CTCL. Demonstration of a T-cell clone (preferably of the same T-cell clone in skin and peripheral blood) in combination with one of the aforementioned cytomorphological or immunophenotypical criteria has been suggested as minimal criteria for the diagnosis of SS, in order to exclude patients with benign inflammatory conditions simulating SS.

Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell neoplasm etiologically linked with the human T-cell leukemia virus 1 (HTLV-1). Cutaneous lesions are usually a manifestation of widely disseminated disease, although a slowly progressive form that may only involve the skin may occur.8

Subcutaneous panniculitislike T-cell lymphoma (SPTL) is a cytotoxic T-cell lymphoma characterized by the presence of primarily subcutaneous infiltrates of small, medium, or large pleomorphic T cells and many macrophages, predominantly affecting the legs and often complicated by a hemophagocytic syndrome.9 At least 2 groups of SPTL with different histologies, phenotypes, and prognoses can be distinguished. Cases with an alpha/beta-positive T-cell phenotype are usually CD8+, are restricted to the subcutaneous tissue (with no dermal or epidermal involvement), and tend to run an indolent clinical course.10,11 The SPTL designation is only used for patients with an alpha/beta-positive T-cell phenotype, whereas those with a gamma/delta T-cell phenotype are now categorized as having CGD-TCL.1,2,3,11,12

Extranodal NK/T-cell lymphoma, nasal type, is an Epstein-Barr virus (EBV)–positive lymphoma of small, medium, or large cells, usually with an NK-cell, or, more rarely, a cytotoxic T-cell phenotype. The skin is the second most common site of involvement, with the nasal cavity/nasopharynx being the most common and the reason why it was once known as a lethal midline granuloma. Cutaneous involvement may be primary or secondary. Because both primary and secondary involvement are clinically aggressive and require the same type of treatment, distinction between the 2 cutaneous involvements seems unnecessary.11,13,14

Primary cutaneous PTL, type unspecified, is the designation for CTCLs that do not fit into any of the better-defined subtypes of CTCL.1,2,3 These include the 3 provisional entities described below, because primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, CGD-TCL, and primary cutaneous small-medium CD4+ T-cell lymphoma can be separated out as provisional entities. The remaining diseases that do not fit into any of the better-defined subtypes of CTCL are characterized as follows:

  • Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, a provisional entity, is characterized by a proliferation of epidermotropic CD8+ cytotoxic T cells and aggressive clinical behavior.5
  • CGD-TCL is composed of a clonal proliferation of mature, activated gamma/delta T cells with a cytotoxic phenotype.12,15,16 It may be primary or secondary cutaneous lymphoma.
  • Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma is the diagnosis used when a predominance of small- to medium-sized CD4+ pleomorphic T cells are present without a history of patches and plaques typical of MF.17

For additional information from other eMedicine articles, see T-Cell Disorders, Mycosis Fungoides, and Lymphoma, Cutaneous T-Cell.

Pathophysiology

The primary pathophysiologic mechanisms for the development of cutaneous T-cell lymphoma (CTCL) (ie, MF) have not been elucidated. MF may be preceded by a T-cell–mediated chronic inflammatory skin disease, which may occasionally progress to a fatal lymphoma. Karyotypic analysis of cutaneous and blood lymphocytes has shown several genetically aberrant T-cell clones in the same patient.

A genotraumatic T cell is one with a tendency to develop numerous clonal chromosomal aberrations. Normal T lymphocytes show apoptosis during in vitro culturing, whereas genotraumatic ones have the ability to develop clonal chromosomal aberrations to become immortalized. This concept implies genetic instability followed by T-cell proliferation. Successive cell divisions of a genotraumatic T-cell clone may produce multiple and complex chromosomal aberrations. Some may reprogram the genotraumatic cells to apoptosis, whereas one or more may produce the phenotypic alterations of malignancy if not eliminated in vivo.

Thus, one hypothesis is that the development of genotraumatic T lymphocytes is involved in the etiopathogenesis and the progression of MF. It would also predict that each patient would likely have a unique malignant clone, which, in fact, has been found to be the case.

CTCL is a group of T-cell proliferative disorders. Primary cutaneous lymphomas require distinction from histologically similar primary nodal ones because their clinical behavior, prognosis, and therapy are often different. In addition, a difference often exists between primary cutaneous and nodal lymphomas in the presence of specific translocations.

Frequency

United States

The incidence of CTCL is approximately 5 cases per million population per year.

International

Cutaneous T-cell lymphomas (CTCLs) account for 65% of cutaneous lymphomas. CTCLs have a worldwide distribution, with no well-identified increase in prevalence in any region. Some studies have identified an increase in prevalence in industrial populations (eg, among workers who use machine cutting oils). ATLL is endemic in areas with a high prevalence of HTLV-1 infection, such as southwest Japan, the Caribbean islands, South America, and parts of Central Africa. ATLL occurs in 1-5% of seropositive individuals after more than 2 decades of viral persistence.8 Nasal NK/T-cell lymphoma, which is associated with EBV infection, is more common in Asia, Central America, and South America.

Race

In the United States, CTCL is more common among Americans of sub-Saharan African lineage than those of European background, in a ratio of approximately 2:1.

Sex

CTCL is more common in men in a ratio of approximately 2:1.

Age

Most patients with CTCL are middle-aged or elderly. Many patients have had a poorly defined form of dermatitis for many years prior to the onset of CTCL. In a significant proportion of cases, the onset of the disease, or of a dermatitic precursor of the disease, occurred in childhood. CTCL starting in children younger than 10 years is exceedingly rare and does not show a male predominance; one series even reported a strong female predilection. Similar to adult patients, however, most children present in stage IA or IB and have a good-to-excellent prognosis with treatment, although cases progressing to plaque, tumor-stage disease, and death have been reported. Some patients with limited MF are described as having Woringer-Kolopp–type pagetoid reticulosis. These patients are usually middle-aged, with an age distribution in one series ranging from 13-68 years and a mean age of 55 years.

Clinical

History

Classic MF

Classic cutaneous T-cell lymphoma (CTCL) or mycosis fungoides (MF) is divided into 3 stages: patch (atrophic or nonatrophic), plaque, and tumor. Often, the first stage goes on for many years and is characterized by a nonspecific dermatitis usually consisting of patches, often on the lower trunk and buttocks. Sometimes, these patches have a thin, wrinkled quality, often with reticulated pigmentation. In this stage, pruritus is usually minimal or absent.

Stages IA and IB

Classic MF is usually preceded by a nonspecific indolent inflammatory process, manifesting as atopic dermatitis, nonspecific chronic dermatitis, or parapsoriasis, most commonly large-plaque parapsoriasis, which may progress over years to decades to early plaque-stage MF. Some authorities regard large-plaque parapsoriasis as patch-stage MF. In many cases, the disease never progresses beyond this stage, and the diagnosis of MF is never confirmed. In other cases, the disease appears from the beginning as rather well-defined superficial plaques that range from 2 cm to more than 20 cm in greatest diameter.

While well-developed plaques that are clinically diagnostic for MF are usually intensely pruritic, less characteristic ones typically are not, and the development of pruritus in such lesions is a sign of progression towards MF. Depending on whether the lesions involve up to 10% or involve 10% or more of the body surface, such cases are classified as stage IA or IB, respectively. Many cases remain at these stages for many years or decades without further progression.

Stages IIA and IIB

Clinical lymphadenopathy may develop (stage IIA), sometimes with progression of the plaques to form tumors (stage IIB), or tumors may form from plaques in the absence of lymphadenopathy (stage IIB). Either process usually takes years or even decades to develop. Once tumors form, they are prone to ulceration.

D'emblee MF

The sudden multifocal development tumors of apparent MF may rarely occur without preceding patches or plaques. Most, if not all, such cases probably represent primary cutaneous CD30+ pleomorphic, medium or large cell T-cell lymphomas.

Stage IVA and stage IVB

Development of lymph nodes histologically positive for tumor (stage IVA) and/or visceral lesions (stage IVB) may occur rather rapidly after tumor-stage disease develops and/or clinical lymphadenopathy is detected. Alternatively, either or both may arise from erythrodermic disease (stage III) at a very variable rate. Both are associated with a poor prognosis.

Transformation of MF

MF in any stage may suddenly become much more aggressive, progressing rapidly to more advanced stages. This is associated with the histologic appearance of large atypical cells; often, these are CD30+, and the process is termed large cell transformation.

Pagetoid reticulosis, localized (Woringer-Kolopp) type

Patients with this condition are usually first seen with a solitary psoriasiform or hyperkeratotic patch or plaque, which is usually localized on the extremities; it is slowly progressive. In contrast to classic MF, extracutaneous dissemination or disease-related deaths rarely occur.

Multilesional pagetoid reticulosis (Ketron-Goodman disease) has a clinical course similar to MF and is regarded as a variant of MF. Some cases may actually represent primary cutaneous epidermotropic CD8+ (cytotoxic) T-cell lymphoma.

Erythrodermic (stage III) MF

MF evident as an erythroderma but with too few circulating lymphocytes to warrant a diagnosis of SS is designated erythrodermic MF. Dermatopathic lymphadenopathy is present in these cases.

Variants of MF

  • Folliculotropic MF (FMF) is commonly first evident clinically with alopecia, follicular cysts, or comedolike lesions and is usually associated with follicular mucinosis and strong epidermotropism.18 When mucin is present, the disease is also called alopecia mucinosa. However, the benign form of alopecia mucinosa, not associated with MF, must be distinguished from MF associated with mucinosis. The most relevant feature, with and without associated follicular mucinosis, is the deep follicular and perifollicular localization of the neoplastic infiltrates, which makes them less accessible to skin-targeted therapies.
  • Hypopigmented MF tends to occur in young, slightly to moderately dark-skinned people of Indian, Latin American, or sub-Saharan African American heritage. It manifests as irregular but fairly well-demarcated hypopigmented or white patches. They are asymptomatic or are slightly pruritic and may appear with or without other lesions typical of MF.
  • A granulomatous reaction pattern occasionally is seen in MF and its variants.
  • Bullous MF manifests with flaccid, tense, or ruptured bullae arising on normal skin, an erythematous base, or within typical patch- or plaque-stage lesions of MF. It tends to arise on the trunk and extremities. Rarely, it may clinically resemble pemphigus vulgaris or even erythema multiforme.
  • Pustular MF is often limited to the palms, but the lesions may occur elsewhere.
  • Hyperpigmented MF is diffuse macular hyperpigmentation accompanied by typical MF, or, rarely, the hyperpigmentation may be the only manifestation. These lesions may resemble ashy dermatosis or may appear as more or less well-defined macules. Ultrastructural studies have revealed atypical lymphocytes and keratinocytes, macrophages, and Langerhans cells that contain giant melanosomes within lysosomes.
  • Unilesional MF manifests as a single area of otherwise typical MF that, by definition, comprises a single lesion. Histological changes are identical to those that occur with multiple disseminated lesions of MF. The prognosis is excellent following treatment, although it may recur after surgical excision. In addition to hair follicles, atypical cells in MF may rarely be tropic to eccrine glands. In the even rarer syringotropic MF (syringolymphoid hyperplasia), these are the principal or only lesions observed. Both the eccrine duct and the eccrine gland are typically involved and eccrine epithelium may appear hyperchromatic and atypical, mimicking eccrine carcinoma. Lesions manifest as red to skin-colored papules, red-to-brown patches, or red scaly plaques. Hair loss without mucinous degeneration in the affected areas is common. All reported cases to date have been in men.
  • Pagetoid reticulosis (Woringer-Kolopp disease) arises preferentially on acral skin as a single, slowly growing psoriasiform plaque. Dissemination or extracutaneous manifestation does not occur. The histologic hallmark of the disease is the pagetoid spread of haloed lymphoid cells in the epidermis.
  • Poikilodermic MF is when poikiloderma (ie, poikiloderma vasculare atrophicans, which is a combination of atrophic, dry, dyspigmented skin and telangiectasia) develops in cases of otherwise typical MF; this is not an infrequent occurrence. Occasionally, it may predominate or even be the only presenting manifestation of the disease. It may rarely involve skin over the entire body.
  • Other variants of MF include hyperkeratotic/verrucous and vegetating/papillomatous MF, typically arising in the axillae, perineum, cervical area (neck), and sometimes on the breasts near the areolae, resembling acanthosis nigricans or multiple seborrheic keratosis.
  • Persistent pigmented purpuralike-to-lichenoid processes also may be a manifestation of MF.
  • Mucosal involvement by MF is rare and may occur as part of generalized involvement in advanced cases, particularly those that have undergone large cell transformation; it is a poor prognostic sign.
  • GSS syndrome is a distinct subtype of MF characterized by ponderous, more-or-less infiltrated folds of skin that arise slowly in intertriginous areas, especially the axillae and groin. GSS syndrome may give rise to Hodgkin disease.
Sézary syndrome

The combination of erythroderma and leukemia is defined as SS. However, different clinicians use different criteria regarding the number of circulating atypical lymphocytes sufficient to warrant this diagnosis. According to some, the diagnosis is established in an erythrodermic patient if more than 5% of peripheral lymphocytes are atypical. Others use the absolute number of atypical lymphocytes in the peripheral blood (>1000/µL). In obvious cases, some use a quick and easy criterion of greater than 10 CD4+ T cells for every CD8+ T cell.

Lymphadenopathy is usually present, and the skin itself is usually edematous. Other frequently observed changes include palmar and/or plantar hyperkeratosis, alopecia, nail dystrophy, and ectropion. Hepatosplenomegaly may be present. As in other forms of MF, a nonspecific dermatitis and/or pruritus may precede the disease. Transformation of the disease to a more aggressive form is common. It may occur in lymph nodes even as skin lesions are showing improvement or a response to treatment.

Extranodal NK/T-cell lymphoma, nasal type

Extranodal nasal-type NK/T-cell lymphoma is an EBV-positive lymphoma of small, medium, or large cells with an NK-cell or cytotoxic T-cell phenotype.19

Physical

Mycosis fungoides (MF) is a commonly epidermotropic cutaneous T-cell lymphoma (CTCL) characterized by small-to-medium T lymphocytes with cerebriform nuclei. The term MF is used only for the classic Alibert-Bazin type characterized by the evolution of patches, plaques, and tumors or for variants showing a similar clinical course. MF is the most common form of CTCL and accounts for almost 50% of all primary cutaneous lymphomas. MF has an indolent clinical course with slow progression over years or decades, from patches to more infiltrated plaques and, eventually, tumors.

  • Initially, MF has a predilection for the buttocks and other sun-protected areas. In tumor-stage MF, the usual presentation is a combination of patches, plaques, and tumors; the tumors often show ulceration. However, if only tumors are present, without preceding or concurrent patches or plaques, a diagnosis of MF is highly unlikely and another type of CTCL should be considered.1,2
  • SS occurs almost exclusively in adults. It is characterized by erythroderma, often associated with marked pruritus and exfoliation, edema, and lichenification. Lymphadenopathy, alopecia, onychodystrophy, and palmoplantar hyperkeratosis are commonly associated.
  • GSS syndrome shows circumscribed areas of pendulous lax skin with a predilection for the axillae and groin. An association with Hodgkin lymphoma or with classic MF may be apparent.20 Most patients have an indolent clinical course.
  • Acute ATLL is characterized by the presence of leukemia, lymphadenopathy, organomegaly, hypercalcemia, and, in approximately 50%, skin lesions. Skin lesions most commonly include nodules or tumors (33%), generalized papules (22%), or plaques (19%).8 Chronic and smoldering variants frequently manifest as skin lesions that closely resemble MF, whereas circulating neoplastic T cells are few or absent.
  • SPTL is a rare form of CTCL; only alpha/beta-types are included. Patients are usually first seen with solitary or multiple nodules and plaques, mainly involving the legs, although they may be more generalized. Ulceration is uncommon, but systemic symptoms such as fever, fatigue, and weight loss may be present. A hemophagocytic syndrome may be present and is generally associated with a rapidly progressive course.21 Dissemination to extracutaneous sites is unusual. SPTL may be preceded for years or decades by a seemingly benign panniculitis suggestive of chronic erythema nodosum. Rarely, it may produce scalp alopecia.22
  • Primary cutaneous PTL, unspecified, is a heterogeneous group of diseases for which the common characteristic is a lack of typical features of MF.
  • Cutaneous gamma/delta T-cell lymphoma12 belongs to the PTL group.2,3 It usually has an aggressive course and manifests with disseminated plaques and/or ulceronecrotic nodules or tumors, particularly on the extremities.23
  • Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, provisional entity, manifests localized or disseminated eruptive papules, nodules, and tumors that show central ulceration and necrosis or superficial, hyperkeratotic patches and plaques.5,24
  • Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma tends to be first apparent as a solitary plaque or tumor, generally on the face, neck, or upper trunk, although it may less commonly appear as one or several papules, nodules, or tumors.17,25
  • Extranodal NK/T-cell lymphoma, nasal type, usually appears as a midfacial destructive tumor or multiple plaques or tumors, often with ulceration, preferentially on the trunk and extremities. Systemic symptoms such as fever, malaise, and weight loss may be present, and some cases are accompanied by a hemophagocytic syndrome. Extranodal NK/T-cell lymphoma, nasal type, has a variant that clinically resembles hydroa vacciniforme in which children, mainly in Latin America and Asia, have a papulovesicular eruption that typically occurs on sun-exposed areas such as the face and upper extremities.26,27

Causes

Chemical, physical, and microbial irritants have been discussed, but evidence related to an etiology is not convincing.1 They may play the role of a persistent antigen, which, in a stepwise process, leads to an accumulation of mutations in oncogenes, suppressor genes, and signal-transducing genes.3

More on Cutaneous T-Cell Lymphoma

Overview: Cutaneous T-Cell Lymphoma
Differential Diagnoses & Workup: Cutaneous T-Cell Lymphoma
Treatment & Medication: Cutaneous T-Cell Lymphoma
Follow-up: Cutaneous T-Cell Lymphoma
Multimedia: Cutaneous T-Cell Lymphoma
References
[ CLOSE WINDOW ]

References

  1. Burg G, Kempf W. Etiology and pathogenesis of cutaneous lymphomas. In: Burg G, Kempf W. Cutaneous Lymphomas. London: Taylor & Francis; 2005.

  2. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. May 15 2005;105(10):3768-85. [Medline].

  3. Burg G, Kempf W, Cozzio A, Dobbeling U, Feit J, Golling P, et al. Cutaneous malignant lymphomas: update 2006. J Dtsch Dermatol Ges. Nov 2006;4(11):914-33. [Medline].

  4. Khamaysi Z, Ben-Arieh Y, Izhak OB, Epelbaum R, Dann EJ, Bergman R. The Applicability of the New WHO-EORTC Classification of Primary Cutaneous Lymphomas to a Single Referral Center. Am J Dermatopathol. Feb 2008;30(1):37-44. [Medline].

  5. Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. Aug 1999;155(2):483-92. [Medline].

  6. Kempf W, Ostheeren-Michaelis S, Paulli M, Lucioni M, Wechsler J, Audring H, et al. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol. Dec 2008;144(12):1609-17. [Medline].

  7. Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. Jan 2002;46(1):95-106. [Medline].

  8. Setoyama M, Katahira Y, Kanzaki T. Clinicopathologic analysis of 124 cases of adult T-cell leukemia/lymphoma with cutaneous manifestations: the smouldering type with skin manifestations has a poorer prognosis than previously thought. J Dermatol. Dec 1999;26(12):785-90. [Medline].

  9. Weenig RH, Ng CS, Perniciaro C. Subcutaneous panniculitis-like T-cell lymphoma: an elusive case presenting as lipomembranous panniculitis and a review of 72 cases in the literature. Am J Dermatopathol. Jun 2001;23(3):206-15. [Medline].

  10. Hoque SR, Child FJ, Whittaker SJ, Ferreira S, Orchard G, Jenner K, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. Mar 2003;148(3):516-25. [Medline].

  11. Massone C, Chott A, Metze D, Kerl K, Citarella L, Vale E, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. Jun 2004;28(6):719-35. [Medline].

  12. Burg G, Dummer R, Wilhelm M, Nestle F, Ott MM, Feller A, et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med. Oct 10 1991;325(15):1078-81. [Medline].

  13. El Shabrawi-Caelen L, Cerroni L, Kerl H. The clinicopathologic spectrum of cytotoxic lymphomas of the skin. Semin Cutan Med Surg. Jun 2000;19(2):118-23. [Medline].

  14. Miyamoto T, Yoshino T, Takehisa T, Hagari Y, Mihara M. Cutaneous presentation of nasal/nasal type T/NK cell lymphoma: clinicopathological findings of four cases. Br J Dermatol. Sep 1998;139(3):481-7. [Medline].

  15. Arnulf B, Copie-Bergman C, Delfau-Larue MH, Lavergne-Slove A, Bosq J, Wechsler J, et al. Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood. Mar 1 1998;91(5):1723-31. [Medline].

  16. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol. Jul 2003;40(3):175-84. [Medline].

  17. Bekkenk MW, Vermeer MH, Jansen PM, van Marion AM, Canninga-van Dijk MR, Kluin PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. Sep 15 2003;102(6):2213-9. [Medline].

  18. Roeschm A, Schleyer V, Landthaler M, Vogt T. Follicular mycosis fungoides: variability of a rare entity. Skinmed. Jan-Feb 2005;4(1):12-7. [Medline].

  19. Kohler S. Extranodal NK/T-cell lymphoma, nasal type. In: LeBoit P, Burg G, Weedon D, Lyon SA. WHO Books: Tumors of the Skin. Geneva: World Health Organization IARC. X. 2006:191-2.

  20. Clarijs M, Poot F, Laka A, Pirard C, Bourlond A. Granulomatous slack skin: treatment with extensive surgery and review of the literature. Dermatology. 2003;206(4):393-7. [Medline].

  21. Marzano AV, Berti E, Paulli M, Caputo R. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol. Jul 2000;136(7):889-96. [Medline].

  22. Torok L, Gurbity TP, Kirschner A, Krenacs L. Panniculitis-like T-cell lymphoma clinically manifested as alopecia. Br J Dermatol. Oct 2002;147(4):785-8. [Medline].

  23. Toro JR, Liewehr DJ, Pabby N, Sorbara L, Raffeld M, Steinberg SM, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. May 1 2003;101(9):3407-12. [Medline].

  24. Santucci M, Pimpinelli N, Massi D, Kadin ME, Meijer CJ, Muller-Hermelink HK, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. Feb 1 2003;97(3):610-27. [Medline].

  25. von den Driesch P, Coors EA. Localized cutaneous small to medium-sized pleomorphic T-cell lymphoma: a report of 3 cases stable for years. J Am Acad Dermatol. Apr 2002;46(4):531-5. [Medline].

  26. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, Zaharia M, Misad O, Bravo F, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol. Mar 2002;10(1):7-14. [Medline].

  27. Chen HH, Hsiao CH, Chiu HC. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. Br J Dermatol. Sep 2002;147(3):587-91. [Medline].

  28. Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases. Pathol Int. Feb 2008;58(2):89-97. [Medline].

  29. Russell-Jones R. Diagnosing erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. Jul 2005;153(1):1-5. [Medline].

  30. Petrella T, Comeau MR, Maynadie M, Couillault G, De Muret A, Maliszewski CR, et al. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. Jul 2002;26(7):852-62. [Medline].

  31. Smoller BR, Santucci M, Wood GS, Whittaker SJ. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. Dec 2003;17(6):1277-311. [Medline].

  32. Haghighi B, Smoller BR, LeBoit PE, Warnke RA, Sander CA, Kohler S. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol. May 2000;13(5):502-10. [Medline].

  33. Mao X, Lillington D, Scarisbrick JJ, Mitchell T, Czepulkowski B, Russell-Jones R, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides. Br J Dermatol. Sep 2002;147(3):464-75. [Medline].

  34. Burg G, Zwingers T, Staegemeir E, Santucci M. Interrater and intrarater variabilities in the evaluation of cutaneous lymphoproliferative T-cell infiltrates. EORTC-Cutaneous Lymphoma Project Group. Dermatol Clin. Apr 1994;12(2):311-4. [Medline].

  35. Santucci M, Biggeri A, Feller AC, Massi D, Burg G. Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation. European Organization for Research and Treatment of Cancer. Am J Surg Pathol. Jan 2000;24(1):40-50. [Medline].

  36. Santucci M, Smoller B. ISCL study on early diagnosis of mycosis fungoides. (in preparation).

  37. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol. Dec 2005;53(6):1053-63. [Medline].

  38. Zelger B, Sepp N, Weyrer K, Grunewald K, Zelger B. Syringotropic cutaneous T-cell lymphoma: a variant of mycosis fungoides?. Br J Dermatol. Jun 1994;130(6):765-9. [Medline].

  39. Gerami P, Guitart J. Basaloid folliculolymphoid hyperplasia: a distinctive finding in follicular mycosis fungoides. J Cutan Pathol. Dec 2007;34 Suppl 1:29-32. [Medline].

  40. Imai S, Burg G, Braun-Falco O. Mycosis fungoides and Sezary's syndrome show distinct histomorphological features. Dermatologica. 1986;173(3):131-5. [Medline].

  41. Kamarashev J, Burg G, Kempf W, Hess Schmid M, Dummer R. Comparative analysis of histological and immunohistological features in mycosis fungoides and Sézary syndrome. J Cutan Pathol. Sep 1998;25(8):407-12. [Medline].

  42. Sibaud V, Beylot-Barry M, Thiebaut R, Parrens M, Vergier B, Delaunay M, et al. Bone marrow histopathologic and molecular staging in epidermotropic T-cell lymphomas. Am J Clin Pathol. Mar 2003;119(3):414-23. [Medline].

  43. Takeshita M, Okamura S, Oshiro Y, Imayama S, Okamoto S, Matsuki Y, et al. Clinicopathologic differences between 22 cases of CD56-negative and CD56-positive subcutaneous panniculitis-like lymphoma in Japan. Hum Pathol. Feb 2004;35(2):231-9. [Medline].

  44. Beljaards RC, Meijer CJ, Van der Putte SC, Hollema H, Geerts ML, Bezemer PD, et al. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. J Pathol. Jan 1994;172(1):53-60. [Medline].

  45. Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. Jun 15 1997;89(12):4501-13. [Medline].

  46. Natkunam Y, Smoller BR, Zehnder JL, Dorfman RF, Warnke RA. Aggressive cutaneous NK and NK-like T-cell lymphomas: clinicopathologic, immunohistochemical, and molecular analyses of 12 cases. Am J Surg Pathol. May 1999;23(5):571-81. [Medline].

  47. de Wolf-Peeters C, Achten R. gammadelta T-cell lymphomas: a homogeneous entity?. Histopathology. Apr 2000;36(4):294-305. [Medline].

  48. Jones D, Vega F, Sarris AH, Medeiros LJ. CD4-CD8-"Double-negative" cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course. Am J Surg Pathol. Feb 2002;26(2):225-31. [Medline].

  49. Knobler E. Current management strategies for cutaneous T-cell lymphoma. Clin Dermatol. May-Jun 2004;22(3):197-208. [Medline].

  50. Ysebaert L, Truc G, Dalac S, Lambert D, Petrella T, Barillot I, et al. Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys. Mar 15 2004;58(4):1128-34. [Medline].

  51. Onozuka T, Yokota K, Kawashima T, Shimada H, Kodama K, Kobayashi H, et al. An elderly patient with mycosis fungoides successfully treated with chronic low-dose oral etoposide therapy. Clin Exp Dermatol. Jan 2004;29(1):91-2. [Medline].

  52. Dummer R, Urosevic M, Kempf W, Kazakov D, Burg G. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology. 2003;207(1):116-8. [Medline].

  53. Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. Apr 2004;50(4):600-7. [Medline].

  54. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol. Oct 2004;51(4):570-3. [Medline].

  55. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. Oct 1995;9(5):1057-76. [Medline].

  56. Leverkus M, Rose C, Brocker EB, Goebeler M. Follicular cutaneous T-cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones. Br J Dermatol. Jan 2005;152(1):193-4. [Medline].

  57. Jacob R, Scala M, Fung MA. A case of syringotropic cutaneous T-cell lymphoma treated with local radiotherapy. J Am Acad Dermatol. Jan 2009;60(1):152-4. [Medline].

  58. Russell-Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol. Jan 2000;142(1):16-21. [Medline].

  59. Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. Jun 1 2003;101(11):4267-72. [Medline].

  60. Fukushima T, Horio K, Matsuo E, Imanishi D, Yamasaki R, Tsushima H, et al. Successful cord blood transplantation for mycosis fungoides. Int J Hematol. Dec 2008;88(5):596-8. [Medline].

  61. Lambert WC, Cohen PJ, Schwartz RA. Surgical management of mycosis fungoides. J Med. 1997;28(3-4):211-22. [Medline].

  62. Foss F. Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. Leuk Lymphoma. 2003;44 Suppl 3:S55-61. [Medline].

  63. Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. Dec 28 1989;321(26):1784-90. [Medline].

  64. Tancrede-Bohin E, Ionescu MA, de La Salmoniere P, Dupuy A, Rivet J, Rybojad M, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol. Sep 2004;140(9):1057-61. [Medline].

  65. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. Feb 2002;138(2):191-8. [Medline].

  66. Scarisbrick JJ, Whittaker S, Evans AV, Fraser-Andrews EA, Child FJ, Dean A, et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood. Feb 1 2001;97(3):624-30. [Medline].

  67. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. Nov 1991;79(3):428-37. [Medline].

  68. Fink-Puches R, Zenahlik P, Back B, Smolle J, Kerl H, Cerroni L. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. Feb 1 2002;99(3):800-5. [Medline].

  69. Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. Jul 2004;15(7):1097-108. [Medline].

  70. Mraz-Gernhard S, Natkunam Y, Hoppe RT, LeBoit P, Kohler S, Kim YH. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol. Apr 15 2001;19(8):2179-88. [Medline].

  71. Burg G, Kempf W. Therapy of cutaneous lymphomas. In: Burg G, Kempf W. Cutaneous Lymphomas. London: Taylor & Francis; 2005:475-528.

  72. Burg G, Kempf W, Cozzio A, Feit J, Willemze R, S Jaffe E, et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol. Nov 2005;32(10):647-74. [Medline].

  73. Santucci M, Biggeri A, Feller AC, et al. Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation. European Organization for Research and Treatment of Cancer. Am J Surg Pathol. Jan 2000;24(1):40-50. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

CTCL, mycosis fungoides, patch stage mycosis fungoides, large plaque parapsoriasis, plaque stage mycosis fungoides, tumor stage mycosis fungoides, d'emblee mycosis fungoides, primary cutaneous pleomorphic mycosis fungoides, medium-sized T-cell lymphoma, large cell CD30+ T-cell lymphoma, large cell CD30- T-cell lymphomas, solitary mycosis fungoides, unilesional mycosis fungoides, unilesional pagetoid reticulosis, Woringer-Kolopp disease, follicular mycosis fungoides, Sézary syndrome, Sezary syndrome, Sezary's syndrome, erythrodermic mycosis fungoides, granulomatous slack skin, granulomatous CTCL, granulomatous mycosis fungoides, angiocentric CTCL, subcutaneous CTCL, panniculitis-like CTCL, panniculitislike CTCL, lipotropic CTCL, panniculotropic CTCL, subcutaneous mycosis fungoides, suppressor T-cell CTCL, CD8+ CTCL, delta/gamma CTCL, NK cell CTCL, natural killer CTCL, KI-1+ large cell CTCL

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Robert A Schwartz, MD, MPH, Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.

Coauthor(s)

W Clark Lambert, MD, PhD, Professor and Head, Dermatopathology, Departments of Pathology and Dermatology, UMDNJ-New Jersey Medical School
W Clark Lambert, MD, PhD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Dermatological Association, American Society of Dermatopathology, International Academy of Pathology, Medical Society of New Jersey, Sigma Xi, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

Medical Editor

Günter Burg, MD, Professor and Chairman Emeritus, Department of Dermatology, University of Zürich School of Medicine; Delegate of The Foundation for Modern Teaching and Learning in Medicine Faculty of Medicine, University of Zürich, Switzerland
Günter Burg, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, International Society for Dermatologic Surgery, North American Clinical Dermatologic Society, and Pacific Dermatologic Association
Disclosure: Nothing to disclose.

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Managing Editor

Jeffrey Meffert, MD, Assistant Clinical Professor of Dermatology, University of Texas Health Science Center-San Antonio
Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, and Texas Dermatological Society
Disclosure: Nothing to disclose.

CME Editor

Catherine M Quirk, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania
Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.